Rheumatology Doctors in Bettendorf, IA Accepting Medicare

3 Rheumatology doctors found. Showing 1 - 3

David B Staub, M.D. Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3740 Utica Ridge Rd Ste A, Bettendorf, IA 52722 Phone: 563-359-4440    Fax: 563-359-4644

Sunita Kammila Penmatcha, M.D. Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3740 Utica Ridge Rd, Bettendorf, IA 52722 Phone: 563-359-4440    Fax: 563-359-4644

Mudappa Karineravanda Kalaiah, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2979 Victoria St, Bettendorf, IA 52722 Phone: 563-359-4440

News Archive

Drinking alcohol leads to release of endorphins in the brain

Drinking alcohol leads to the release of endorphins in areas of the brain that produce feelings of pleasure and reward, according to a study led by researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco.

Reuters examines maternal mortality in Afghanistan

"An Afghan woman can expect to have an average 5.1 babies in her lifetime, the highest fertility rate in Asia," Reuters writes in the first of two articles examining childbirth and maternal mortality in Afghanistan. The news service adds that "giving birth a common, and frequent experience - but mothers say it is too often also hard, lonely and frightening."

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. entered into a co-promotion agreement for EYLEA aflibercept) Injection in Japan.

Understanding diversity in disease - new routes to prevention, diagnosis and treatment

The Medical Research Council (MRC), the National Institute for Health Research (NIHR) and the health research departments in Northern Ireland, Scotland and Wales have launched a joint initiative of more than £6millon to identify small carefully defined groups of patients to help researchers detect, treat or prevent diseases.

Existing drug masitinib identified as potential inhibitor of SARS-CoV-2

Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

Read more Medical News

› Verified 7 days ago